Patents by Inventor Richard J. Armitage

Richard J. Armitage has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD30 Ligand
    Publication number: 20090264349
    Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.
    Type: Application
    Filed: May 9, 2007
    Publication date: October 22, 2009
    Applicant: Immunex Corporation
    Inventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage, Hans-Juergen Gruss
  • CD40-Ligand lacking native-pattern glycosylation
    Patent number: 7405270
    Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor and lack native-pattern glycosylation.
    Type: Grant
    Filed: July 19, 2002
    Date of Patent: July 29, 2008
    Assignee: Immunex Corporation
    Inventors: Richard J. Armitage, William C. Fanslow, III, Melanie K. Spriggs
  • Mouse CD40 ligand-specific antibodies and hybridomas
    Patent number: 7309489
    Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor.
    Type: Grant
    Filed: May 28, 1999
    Date of Patent: December 18, 2007
    Assignee: IMMUNEX Corporation
    Inventors: Richard J. Armitage, William C. Fanslow, Melanie K. Spriggs
  • CD30 ligand
    Patent number: 7232660
    Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: June 19, 2007
    Assignee: Immunex Corporation
    Inventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage
  • CD 30 ligand
    Publication number: 20040241758
    Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.
    Type: Application
    Filed: October 2, 2003
    Publication date: December 2, 2004
    Applicant: IMMUNEX CORPORATION
    Inventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage, Hans-Juergen Gruss
  • CD40-Ligand lacking native-pattern glycosylation
    Publication number: 20040006006
    Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor and lack native-pattern glycosylation.
    Type: Application
    Filed: July 19, 2002
    Publication date: January 8, 2004
    Inventors: Richard J. Armitage, William C. Fanslow, Melanie K. Spriggs
  • CD30 ligand
    Patent number: 6667039
    Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplasdic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.
    Type: Grant
    Filed: July 28, 2000
    Date of Patent: December 23, 2003
    Assignee: Immunex Corporation
    Inventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage, Hans-Juergen Gruss
  • Defective CD4+T-cells that express active CD40-L
    Patent number: 6613320
    Abstract: CD4+ cells obtained from individuals with defective CD40L gene and transfected with a vector containing CD40-L are described.
    Type: Grant
    Filed: April 10, 2000
    Date of Patent: September 2, 2003
    Assignee: Immunex Corporation
    Inventors: Melanie K. Spriggs, Richard J. Armitage, William C. Fanslow, III, Michael B. Widmer, Barry L. Davison, Blair R. Renshaw
  • CD40-Ligand lacking native-pattern glycosylation
    Publication number: 20030144182
    Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor and lack native-pattern glycosylation.
    Type: Application
    Filed: July 19, 2002
    Publication date: July 31, 2003
    Inventors: Richard J. Armitage, William C. Fanslow, Melanie K. Spriggs
  • METHODS OF TREATING AN UNDESIRED IMMUNE RESPONSE BY BLOCKING THE BINDING 0F CD40 LIGAND TO CD40
    Publication number: 20030091564
    Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor.
    Type: Application
    Filed: August 2, 1999
    Publication date: May 15, 2003
    Inventors: RICHARD J. ARMITAGE, WILLIAM C. FANSLOW, MELANIE K. SPRIGGS, SUBHASHINI SRINIVASAN, MARYLOU G. GIBSON
  • DNA encoding CD40 ligand, a cytokine that binds CD40
    Patent number: 6410711
    Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor.
    Type: Grant
    Filed: September 20, 1999
    Date of Patent: June 25, 2002
    Assignee: Immunex Corporation
    Inventors: Richard J. Armitage, William C. Fanslow, Melanie K. Spriggs, Subhashini Srinivasan, Marylou G. Gibson, Arvia E. Morris, Jeffrey T. McGrew
  • Use of CD40 ligand, a cytokine that binds CD40, to stimulate hybridoma cells
    Patent number: 6391637
    Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor. Also disclosed are methods of simulating hybridoma cells to increase monoclonal antibody production by administering a CD40 ligand polypeptide that stimulates B cell proliferation.
    Type: Grant
    Filed: December 19, 1996
    Date of Patent: May 21, 2002
    Inventors: Richard J. Armitage, William C. Fanslow, Melanie K. Spriggs, Subhashini Srinivasan, Marylou G. Gibson
  • Method of augmenting a vaccine response by administering CD40 ligand
    Patent number: 6290972
    Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor.
    Type: Grant
    Filed: December 19, 1996
    Date of Patent: September 18, 2001
    Assignee: Immunex Corporation
    Inventors: Richard J. Armitage, William C. Fanslow, Melanie K. Spriggs, Subhashini Srinivasan, Marylou G. Gibson
  • Methods of inhibiting CD40L binding to CD40 with soluble monomeric CD40L
    Patent number: 6264951
    Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor. Also disclosed are methods of inhibiting undesirable immune responses, preventing T cell interaction with B cells by blocking CD40L binding to CD40 sites on B cells and other target cells.
    Type: Grant
    Filed: December 19, 1996
    Date of Patent: July 24, 2001
    Assignee: Immunex Corporation
    Inventors: Richard J. Armitage, William C. Fanslow, Melanie K. Spriggs, Subhashini Srinivasan, Marylou G. Gibson
  • CD30 ligand oligomers and polypeptides
    Patent number: 6143869
    Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.
    Type: Grant
    Filed: May 15, 1998
    Date of Patent: November 7, 2000
    Assignee: Immunex Corporation
    Inventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage, Hans-Juergen Gruss
  • Treatment of individuals exhibiting defective CD40L
    Patent number: 6106832
    Abstract: There is disclosed a method of detecting a mutation in a CD40 ligand gene, comprising isolating nucleic acid from an individual, selectively amplifying nucleic acid derived from the CD40 ligand gene, and analyzing the amplified nucleic acid to determine if there is a mutation (or mutations) in the CD40 ligand gene. The ability of a CD40 ligand protein expressed from the gene may be determined. Methods of treating individuals exhibiting a defective CD40 ligand gene (i.e., X-linked hyper IgM patients and certain individuals afflicted with combined variable immunodeficiency) are also disclosed. Also disclosed are non-human animals that lack functional CD40 ligand as a result of gene targeting technology.
    Type: Grant
    Filed: January 22, 1996
    Date of Patent: August 22, 2000
    Assignee: Immunex Corporation
    Inventors: Melanie K. Spriggs, Richard J. Armitage, William C. Fanslow, III, Michael B. Widmer
  • CD40 ligand polypeptide
    Patent number: 6087329
    Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor.
    Type: Grant
    Filed: June 2, 1998
    Date of Patent: July 11, 2000
    Assignee: Immunex Corporation
    Inventors: Richard J. Armitage, William C. Fanslow, Melanie K. Spriggs
  • DNA encoding CD40 ligand, a cytokine that binds CD40
    Patent number: 5981724
    Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 9, 1999
    Assignee: Immunex Corporation
    Inventors: Richard J. Armitage, William C. Fanslow, Melanie K. Spriggs, Subhashini Srinivasan, Marylou G. Gibson, Arvia E. Morris, Jeffrey T. McGrew
  • Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
    Patent number: 5962406
    Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 5, 1999
    Assignee: Immunex Corporation
    Inventors: Richard J. Armitage, William C. Fanslow, Melanie K. Spriggs, Subhashini Srinivasan, Marylou G. Gibson, Arvia E. Morris, Jeffrey T. McGrew
  • Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
    Patent number: 5961974
    Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor.
    Type: Grant
    Filed: May 24, 1994
    Date of Patent: October 5, 1999
    Assignee: Immunex Corporation
    Inventors: Richard J. Armitage, William C. Fanslow, Melanie K. Spriggs